A Randomized Double-blind Placebo-controlled Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects

Trial Profile

A Randomized Double-blind Placebo-controlled Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Adrecizumab (Primary)
  • Indications Septic shock
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 25 Sep 2017 Results published in an Adrenomed Media Release
    • 25 Sep 2017 According to an Adrenomed media release, Dr Christopher Geven is lead investigator of this and other Phase I study (see profile 282845)
    • 25 Sep 2017 According to an Adrenomed media release, data from this trial will be presented at the European Society of Intensive Care Medicine (ESICM) conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top